CMClare McCormack

Clare McCormack

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Clare McCormack has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An Economic Evaluation of Dengue Vaccination with Qdenga in Thailand: Findings from a Dynamic Transmission Model

    by Jarawee Sukmanee, Neil M. Ferguson, Phornnaphat Chertchinnapa, Clare McCormack, Anna Vicco, Bethan Cracknell Daniels, Sunate Chuenkitmongkol, Nakorn Premsri, Yot Teerawattananon, Ilaria Dorigatti, et al.

    Background: Dengue is highly endemic in many tropical and subtropical regions, including Thailand. As no specific treatment is available, vaccination is an important preventive strategy. The Qdenga (TAK-003) live-attenuated quadrivalent dengue vaccine is recommended by the World Health Organization for routine immunisation programmes in high-transmission settings with substantial disease burden. However, an independent country-specific economic evaluation is needed before inclusion in Thailand's National Immunization Program. This study evaluated the cost-effectiveness and budget impact of Qdenga vaccination strategies in Thailand.Methods: Cost-utility and budget impact analyses were conducted using a previously developed dengue transmission model. Qdenga vaccination scenarios, varying by vaccination age, vaccine mode of action (protection against disease only or against both disease and infection), and duration of waning (5 or 10 years), were compared with a no vaccination comparator. Costs and health outcomes, measured in quality-adjusted life years (QALYs), were projected over a 30-year time horizon.Findings: A national vaccination programme cumulatively targeting 15 million children aged 6 years could prevent 1·7 million symptomatic dengue cases and 382,000 hospitalisations. In the base-case analysis, routine vaccination targeting 6-year-olds would generate incremental costs of US$1,186 million and gain of 41,169 QALYs, resulting in an ICER of US$30,458/QALY. This exceeds Thailand's cost-effectiveness threshold (US$4,739/QALY) and yields an incremental net monetary benefit of –US$996 million. The annual government budget impact over the first five years was estimated to vary between US$66·4–70·9 million.Interpretation: Qdenga vaccination could substantially reduce symptomatic dengue cases and hospitalisations in Thailand. However, at its current price, the programme is unlikely to be cost-effective and would have a considerable budget impact. Price negotiation is therefore recommended before inclusion in the national immunisation programme.

  • Open Access

    Combining vaccination with w Mel for dengue control in Brazil

    by Emilie Finch, Angkana T. Huang, Clare McCormack, Anna Vicco, Julio Croda, Neil M. Ferguson, Ilaria Dorigatti, Henrik Salje

    Dengue virus is a severe threat to global health. Novel vaccine and Wolbachia technologies offer a potential path to dengue control; however, it remains unclear how to use these approaches in tandem. Using metapopulation transmission models, we simulated future dengue burden in Brazil. We estimated that w Mel releases in 300 municipalities could avert 12-22% of cases over the next 10 years, while a national vaccination campaign could avert 8-10% of cases in the total population and 39-45% within the vaccinated cohort. Projecting forward 40 years, we found w Mel releases would drive up the mean age of cases beyond increases due to the ageing population and increase population susceptibility to dengue. Finally, w Mel releases can help mitigate the future burden in southern Brazil where climate change is rapidly increasing dengue virus risk. These findings highlight the need to consider the two technologies in parallel to optimise efforts to combat future dengue burden.

  • Open Access

    Estimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infection

    by Clare McCormack, Olivia Goethals, Nele Goeyvaerts, Xavier Woot De Trixhe, Babs Verstrepen, Liesbeth van Wesenbeek, Ernst Verschoor, Suzanne J. Kaptein, Johan Neyts, Marnix Van Loock, et al.

    Almost half of the world's population is at risk of acquiring dengue virus (DENV) each year. However, no specific licensed prophylactic or antiviral treatment for dengue currently exists. Mosnodenvir, a novel DENV inhibitor, has been shown to inhibit DENV replication in vitro and in animal studies. Here, we provide new insights into the in vivo prophylactic inhibitory effect of mosnodenvir exposure on primary DENV-2 infection by fitting mechanistic within-host models of DENV infection to virological and serological data observed from pre-clinical challenge studies in AG129 mice and rhesus macaques. We estimated a median mosnodenvir concentration achieving 50% of maximal inhibitory effect (IC50) on viral replication of 8.35 (6.82, 9.22) ng ml−1 and 7.61 (5.67, 8.92) ng ml−1 for AG129 mice and rhesus macaques, respectively. A higher concentration is typically required to suppress viral replication in AG129 mice compared with rhesus macaques owing to a higher estimated within-host basic reproduction number (R0) in mice. By integrating multiple data types in a single framework, this study enhances our understanding of the within-host dynamics of primary DENV infection in non-human host species. Furthermore, the methods developed here could possibly assist in quantifying the prophylactic inhibitory effect of mosnodenvir on DENV infections in humans.


  • Open Access

    Examining gender and ethnic disparities in scientific authorship to promote a culture of equity, diversity and inclusion at a university school of public health

    by Paula Christen, Julia Michalow, Tristan Naidoo, Hillary Topazian, Sabine L. van Elsland, Abeer M. Arif, Marc Baguelin, Gemma Clunie, Sarah Essilfie-Quaye, Daniela Fecht, et al.

    In public health research, diverse perspectives are vital to identify biases that homogenous teams might miss. Since publication metrics influence career progression, we investigated publication rate disparities within a School of Public Health. We analysed 18 322 peer-reviewed publications by 513 affiliated researchers between 2014 and 2023 using multivariable regression models and network analysis to assess the impact of gender, ethnicity, job level and centrality in the School’s research network on publication rates. We found a persistent gender gap in publication rates across job levels and ethnicities, with men publishing more than women (incidence rate ratio 1.30, 95% confidence interval (CI): 1.15–1.46). This disparity was present from early career levels and amplified in senior roles, where men were over-represented (71.2% of men at Professor level). Unadjusted analyses indicated higher publication rates for white researchers (median of one publication more per person per year). The COVID-19 pandemic led to increased publication rates for both genders, but the gender gap persisted, with men publishing 1.27 (95% CI: 1.10–1.46) times more than women in 2020/2021. This study underscores the need to identify and address root causes of these disparities to foster an inclusive research environment where diverse contributions are recognized and valued.


  • Open Access

    Examining gender and ethnic disparities in scientific authorship to promote a culture of equity, diversity and inclusion at a university school of public health

    by Paula Christen, Julia Michalow, Tristan Naidoo, Hillary Topazian, Sabine van Elsland, Abeer M Arif, Marc Baguelin, Gemma Clunie, Daniela Fecht, Tini Garske, et al.

    While fostering equity, diversity, and inclusion in the workplace is crucial for many reasons, in public health research, diverse perspectives are particularly vital to identify biases that homogenous teams might miss. Given that publication metrics often influence career progression, we investigated gender and ethnic disparities in publication rates within Imperial College London’s School of Public Health. We analysed 18,322 peer-reviewed publications by 513 affiliated researchers between 2014 and 2023. We used mixed-effects multivariable regression models to assess the impact of gender, ethnicity, and job level on publication rates. Network analysis of co-authorships was performed to evaluate each author’s centrality in the department’s research network. We found a persistent gender gap in publication rates across all job levels and ethnicities, with men publishing more than women (incidence rate ratio (IRR) 1.30 95% Confidence Interval (CI): 1.15 – 1.46). This disparity was present from early career levels and amplified in senior roles, where men were overrepresented (71.2% of men at Professor level). Internal collaboration rates were similar between genders. Unadjusted analyses indicated higher publication rates for white researchers (median of 1 publication more per person per year), although there were limitations in the ethnicity classification algorithm. The COVID-19 pandemic led to increased publication rates for both genders, but the gender gap persisted, with men publishing 1.27 (95% CI: 1.10 – 1.46) times more than women in 2020 - 2021. A complex interplay of factors may contribute to publication disparities, including differences in research contributions, systemic barriers, and potential biases in research allocation, mentorship, and promotion processes. This study underscores the need to identify and address the root causes of these disparities to foster an inclusive research environment where diverse contributions are recognized and valued.


  • Open Access

    A scoping literature review of global dengue age-stratified seroprevalence data: estimating dengue force of infection in endemic countries

    by Anna Vicco, Clare McCormack, Belen Pedrique, Isabela Ribeiro, Gathsaurie Neelika Malavige, Ilaria Dorigatti


  • Open Access

    Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics

    by Clare P McCormack, Olivia Goethals, Nele Goeyvaerts, Xavier D Woot de Trixhe, Peggy Geluykens, Doortje Borrenberghs, Neil M Ferguson, Oliver Ackaert, Ilaria Dorigatti

    Dengue virus (DENV) is a public health challenge across the tropics and subtropics. Currently, there is no licensed prophylactic or antiviral treatment for dengue. The novel DENV inhibitor JNJ-1802 can significantly reduce viral load in mice and non-human primates. Here, using a mechanistic viral kinetic model calibrated against viral RNA data from experimental in-vitro infection studies, we assess the in-vitro inhibitory effect of JNJ-1802 by characterising infection dynamics of two DENV-2 strains in the absence and presence of different JNJ-1802 concentrations. Viral RNA suppression to below the limit of detection was achieved at concentrations of >1.6 nM, with a median concentration exhibiting 50% of maximal inhibitory effect (IC50) of 1.23x10-02 nM and 1.28x10-02 nM for the DENV-2/RL and DENV-2/16681 strains, respectively. This work provides important insight into the in-vitro inhibitory effect of JNJ-1802 and presents a first step towards a modelling framework to support characterization of viral kinetics and drug effect across different host systems.


  • Open Access

    A simulation-based method to inform serosurvey design for estimating the force of infection using existing blood samples

    by Anna Vicco, Clare P McCormack, Belen Pedrique, John H Amuasi, Anthony Afum-Adjei Awuah, Christian Obirikorang, Nicole S Struck, Eva Lorenz, Jürgen May, Isabela Ribeiro, et al.

    The extent to which dengue virus has been circulating globally and especially in Africa is largely unknown. Testing available blood samples from previous cross-sectional serological surveys offers a convenient strategy to investigate past dengue infections, as such serosurveys provide the ideal data to reconstruct the age-dependent immunity profile of the population and to estimate the average per-capita annual risk of infection: the force of infection (FOI), which is a fundamental measure of transmission intensity. In this study, we present a novel methodological approach to inform the size and age distribution of blood samples to test when samples are acquired from previous surveys. The method was used to inform SERODEN, a dengue seroprevalence survey which is currently being conducted in Ghana among other countries utilizing samples previously collected for a SARS-CoV-2 serosurvey. The method described in this paper can be employed to determine sample sizes and testing strategies for different diseases and transmission settings.


  • Open Access

    Modelling the viral dynamics of the SARS-CoV-2 Delta and Omicron variants in different cell types

    by Clare P. McCormack, Ada W. C. Yan, Jonathan C. Brown, Ksenia Sukhova, Thomas P. Peacock, Wendy S. Barclay, Ilaria Dorigatti

    We use viral kinetic models fitted to viral load data from in vitro studies to explain why the SARS-CoV-2 Omicron variant replicates faster than the Delta variant in nasal cells, but slower than Delta in lung cells, which could explain Omicron's higher transmission potential and lower severity. We find that in both nasal and lung cells, viral infectivity is higher for Omicron but the virus production rate is higher for Delta, with an estimated approximately 200-fold increase in infectivity and 100-fold decrease in virus production when comparing Omicron with Delta in nasal cells. However, the differences are unequal between cell types, and ultimately lead to the basic reproduction number and growth rate being higher for Omicron in nasal cells, and higher for Delta in lung cells. In nasal cells, Omicron alone can enter via a TMPRSS2-independent pathway, but it is primarily increased efficiency of TMPRSS2-dependent entry which accounts for Omicron's increased activity. This work paves the way for using within-host mathematical models to understand the transmission potential and severity of future variants.


  • Open Access

    Modelling the viral dynamics of the SARS-CoV-2 Delta and Omicron variants in different cell types

    by Clare P. McCormack, Ada W. C. Yan, Jonathan C. Brown, Ksenia Sukhova, Thomas P. Peacock, Wendy S. Barclay, Ilaria Dorigatti

    We use viral kinetic models fitted to viral load data from in vitro studies to explain why the SARS-CoV-2 Omicron variant replicates faster than the Delta variant in nasal cells, but slower than Delta in lung cells, which could explain Omicron’s higher transmission potential and lower severity. We find that in both nasal and lung cells, viral infectivity is higher for Omicron but the virus production rate is higher for Delta. However, the differences are unequal between cell types, and ultimately leads to the basic reproduction number and growth rate being higher for Omicron in nasal cells, and higher for Delta in lung cells. In nasal cells, Omicron alone can enter via a TMPRSS2-independent pathway, but it is primarily increased efficiency of TMPRSS2-dependent entry which accounts for Omicron’s increased activity. This work paves the way for using within-host mathematical models to understand the transmission potential and severity of future variants.